Back to top
more

Affimed (AFMD)

(Delayed Data from NSDQ)

$4.88 USD

4.88
71,146

0.00 (0.00%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $4.90 +0.02 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 146.7% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Affimed N.V. (AFMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 263.4% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer, Inc. (SEER) delivered earnings and revenue surprises of 20% and 4.79%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 22.22% and 15.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround

by Zacks Equity Research

Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 0% and 68.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of 7.14% and 13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -0.79% and 78.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -2.50% and 29.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Affimed N.V. (AFMD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -4.55% and 26.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -6.78% and 9.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cara (CARA) delivered earnings and revenue surprises of 7.55% and 22.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.14% and 98.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of -30.43% and 4.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 47.06% and 46.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -54.55% and 3.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 13.46% and 166.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

UnitedHealth's (UNH) UnitedHealthcare Unit to Aid Q4 Earnings?

by Zacks Equity Research

An increase in the number of people served in the commercial domestic business of UnitedHealth's (UNH) UnitedHealthcare segment is likely to boost fourth-quarter results.

UnitedHealth (UNH) to Post Q4 Earnings: What You Should Know

by Zacks Equity Research

UnitedHealth Group's (UNH) fourth-quarter results are likely to reflect growing premiums, products and higher expenses.

Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks

by Zacks Equity Research

Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 42.11% and 96.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?